Uridine diphosphate-glucuronosyltransferase 2B15 D85Y gene polymorphism is associated with lower prostate cancer risk: a systematic review and meta-analysis

Xiao Zhong,Jiayu Feng,Ya Xiao,Pingxian Wang,Qiming Fan,Ronghua Wu,Wengang Hu,Chibing Huang
DOI: https://doi.org/10.18632/oncotarget.17375
2017-04-24
Oncotarget
Abstract:UGT2B15 (uridine diphosphate-glucuronosyltransferase 2B15) catalyzes the conversion of lipophilic C19 steroid androgens such as dihydrotestosterone (DHT) into water-soluble metabolites that can be excreted. Studies of the association between the <i>UGT2B15</i> gene D85Y polymorphism and prostate cancer have yielded contradictory results. We therefore systematically searched in the PubMed, EMBASE, Science Direct/Elsevier, CNKI, and Cochrane Library databases, and identified six relevant studies with which to perform a meta-analysis of the relation between <i>UGT2B15</i> D85Y polymorphism and prostate cancer risk. Our meta-analysis revealed a significant association between <i>UGT2B15</i> D85Y gene polymorphism and prostate cancer in all genetic models (P&lt;0.05). The combined odds ratios and 95% confidence intervals were as follows: additive model, 0.53 and 0.32-0.88; dominant model, 0.51 and 0.33-0.79; recessive model, 0.76 and 0.60-0.96; co-dominant model, 0.55 and 0.35-0.86; and allele model, 0.70 and 0.55-0.89. These results are consistent with the idea that the <i>UGT2B15</i> D85Y enzyme variant reduces the risk of prostate cancer by efficiently metabolizing dihydrotestosterone (DHT), which is associated with prostate cancer progression.
What problem does this paper attempt to address?